InBody Co.Ltd (041830) - Cash Flow Conversion Efficiency
Based on the latest financial reports, InBody Co.Ltd (041830) has a cash flow conversion efficiency ratio of 0.032x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩9.04 Billion ≈ $6.13 Million USD) by net assets (₩282.02 Billion ≈ $191.12 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see InBody Co.Ltd (041830) total market value for the company's overall valuation and market capitalisation.
InBody Co.Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how InBody Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
InBody Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of InBody Co.Ltd ranked by their cash flow conversion efficiency. Explore earnings quality score of InBody Co.Ltd to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Elmera Group ASA
OL:ELMRA
|
0.131x |
|
Jinfa Labi Maternity & Baby Articles Co Ltd
SHE:002762
|
-0.014x |
|
Wiscom System Co Ltd
SHE:002090
|
0.071x |
|
Ambassador Hotel Ltd
TW:2704
|
0.009x |
|
Allianz Ayudhya Capital Public Company Limited
BK:AYUD
|
0.040x |
|
Hangzhou Landscape Architecture Design Institute Co Ltd
SHE:300649
|
0.012x |
|
Betterware de México, S.A.P.I. de C.V.
NASDAQ:BWMX
|
0.442x |
|
TA-I Technology Co Ltd
TW:2478
|
0.016x |
Annual Cash Flow Conversion Efficiency for InBody Co.Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of InBody Co.Ltd from 2011 to 2024. View InBody Co.Ltd stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩273.90 Billion ≈ $185.62 Million |
₩28.58 Billion ≈ $19.37 Million |
0.104x | -32.63% |
| 2023-12-31 | ₩249.83 Billion ≈ $169.31 Million |
₩38.69 Billion ≈ $26.22 Million |
0.155x | +9.58% |
| 2022-12-31 | ₩215.26 Billion ≈ $145.88 Million |
₩30.42 Billion ≈ $20.61 Million |
0.141x | -14.45% |
| 2021-12-31 | ₩183.73 Billion ≈ $124.51 Million |
₩30.35 Billion ≈ $20.57 Million |
0.165x | -13.02% |
| 2020-12-31 | ₩150.06 Billion ≈ $101.70 Million |
₩28.50 Billion ≈ $19.31 Million |
0.190x | +9.60% |
| 2019-12-31 | ₩139.69 Billion ≈ $94.67 Million |
₩24.21 Billion ≈ $16.40 Million |
0.173x | +21.74% |
| 2018-12-31 | ₩124.39 Billion ≈ $84.29 Million |
₩17.70 Billion ≈ $12.00 Million |
0.142x | -18.41% |
| 2017-12-31 | ₩106.48 Billion ≈ $72.16 Million |
₩18.58 Billion ≈ $12.59 Million |
0.174x | -11.71% |
| 2016-12-31 | ₩92.30 Billion ≈ $62.55 Million |
₩18.24 Billion ≈ $12.36 Million |
0.198x | +34.91% |
| 2015-12-31 | ₩76.32 Billion ≈ $51.72 Million |
₩11.18 Billion ≈ $7.58 Million |
0.146x | -14.89% |
| 2014-12-31 | ₩59.61 Billion ≈ $40.40 Million |
₩10.26 Billion ≈ $6.95 Million |
0.172x | +26.86% |
| 2013-12-31 | ₩51.56 Billion ≈ $34.94 Million |
₩6.99 Billion ≈ $4.74 Million |
0.136x | +43.70% |
| 2012-12-31 | ₩46.13 Billion ≈ $31.26 Million |
₩4.36 Billion ≈ $2.95 Million |
0.094x | -27.61% |
| 2011-12-31 | ₩42.14 Billion ≈ $28.56 Million |
₩5.50 Billion ≈ $3.72 Million |
0.130x | -- |
About InBody Co.Ltd
InBody Co.,Ltd provides body composition analysis solutions worldwide. The company offers body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, as well as InBody dial and bands. Its products are used in nephrology, liver disease, diabetes, nutrition, and rehabilitation applications. The company was formerly known as Biospace Co., Ltd. InBody Co.,Ltd was foun… Read more